Trial
NCT00953576
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; Prostate Cancer Foundation Clinical Research Consortium; GlaxoSmithKline
Condition
Prostate Cancer
Intervention
ketoconazole
Why stopped
The study terminated early due to concerns about drug toxicity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-04